Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Rituximab 530Cyclophosphamide 425Vincristine 219Doxorubicin 192fludarabine phosphate 177Etoposide 167Prednisone 166fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pharmacokinetics × Lymphoid × Clear all
NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡